7/10/2007

Gilead Sciences announced it is expanding patient access to a new antibiotic being developed by the firm. The drug, designed to fight bacterial infections in cystic fibrosis patients, is to be available at participating treatment centers Aug. 1.

Full Story:
Forbes

Related Summaries